Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio-Rad Introduces Bio-Plex Pro™ RBM Human Metabolic and Hormone Assays

Published: Thursday, July 17, 2014
Last Updated: Thursday, July 17, 2014
Bookmark and Share
Developed in partnership with Myriad RBM, Inc., these multiplex immunoassays permit robust and simultaneous quantification of a highly relevant set of protein biomarkers for the study of diabetes, obesity, and metabolic syndrome, as well as related conditions such as cardiovascular disease and inflammation.

Bio-Rad Laboratories announced the launch of its new Bio-Plex Pro RBM Human Metabolic and Hormone Assays. 

To better understand the relationship between metabolic and cardiovascular conditions, researchers need to study a wide range of disease-associated biomarkers, including gut and pituitary hormones, acute phase proteins, adipokines, nutrient-binding proteins, and growth factors. Because these biomarkers often act in concert, researchers would benefit greatly from the ability to simultaneously measure multiple analytes in a single blood or cell culture sample. The new Bio-Plex Pro RBM Human Metabolic and Hormone Assays were designed to meet this need.

Bio-Plex Pro RBM Human Metabolic and Hormone Assays comprise seven distinct multiplex panels for the detection of 39 analytes, of which 15 are unique to Bio-Rad’s panels. Myriad RBM’s collaboration with Sanofi and the Population Health Research Institute (PHRI) in testing samples from the ORIGIN diabetes clinical trial was instrumental in the selection of markers in these panels.

Benefits of Bio-Plex Pro RBM Assays include:

• Robust performance — validated to meet rigorous analytical standards and manufactured in accordance with GMP guidelines
• Reproducible data — lot-to-lot correlation specification of R2 ≥ 0.9 based on sample testing
• Rapid results — multiplex data in just 3.5 hours through the use of magnetic beads and the fastest assay protocols

Bio-Plex Pro RBM Human Metabolic and Hormone Assays are compatible with the Bio-Plex® 100/200, Bio-Plex 3D, and Bio-Plex® MAGPIX™ Platforms, as well as all other Luminex-based xMAP Instruments and Software.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Presentations at the AACR Annual Meeting to Highlight Advances in Cancer Research Made Possible by Bio-Rad’s Droplet Digital™ PCR Technology
Tailoring Treatments and Tracking Mutations with Liquid Biopsies possible with ddPCR™ technology
Wednesday, April 22, 2015
Bio-Rad Reports Fourth-Quarter and Full-Year 2014 Financial Results
Company has introduced its S3e™ Cell Sorter during the quarter.
Saturday, March 07, 2015
Accurate Determination of Copy Number States for Multiallelic Copy Number Variations
Researchers use next-generation sequencing (NGS) and Bio-Rad’s Droplet Digital PCR (ddPCR™) technology to solve the technical challenge.
Tuesday, March 03, 2015
Awards for Bio-Rad's Protein Expression Products and Genomic Workflow Solutions
BioInformatics LLC has recognized Bio-Rad with two prestigious Life Science Industry Awards for “Best Protein Expression & Analysis Products” and “Best Workflow Solutions — Genomics.”
Monday, January 19, 2015
Quantitative Western Blotting Using Stain-Free Technology
Bio-Rad hosted two seminars at the EB 2014 in which KOLs discussed approaches to improve the accuracy of western blotting quantitation using Bio-Rad’s stain-free technology.
Friday, September 05, 2014
Bio-Rad Acquires Sequencing Technology Company GnuBIO
GnuBIO is a privately-held life sciences company that has developed a droplet-based DNA sequencing technology.
Friday, April 11, 2014
Royal Canadian Mounted Police to Use Bio-Rad’s KnowItAll® Spectroscopy Software for Analysis of Automobile Crime Scene Samples
Using the KnowItAll software to search multiple automobile paint layers found at a crime scene against the PDQ database, forensic scientists can determine the make, model, year, and manufacturing origin of the samples.
Sunday, March 30, 2014
Bio-Rad Partners with the U.S. Pharmacopeial Convention
Company announces the availability of a beta version of the USP Spectral Library™ for raw material identification in the food and drug industries.
Thursday, March 06, 2014
Droplet Digital PCR Enables Measurement of Potential Cancer Survival Biomarker
Study paves the way for further research into the role of TIL quantification in immunotherapy and as a cancer survival predictor.
Tuesday, December 10, 2013
A Brief RT-qPCR “Field Guide” for MIQE Adherence
Bio-Rad’s Sean Taylor and Eli Mrkusich have published a practical guide for MIQE compliance.
Monday, December 09, 2013
Accurate Detection of Extremely Rare Mitochondrial DNA Deletions Associated with Aging
The study published in Aging Cell identifies a new tool to accurately analyze extremely rare mitochondrial DNA deletions associated with a range of diseases and disorders as well as aging.
Thursday, September 05, 2013
Researchers Develop Rapid, Cost-Effective Early Detection Method for Organ Transplant Injury
Chronix Biomedical and transplant expert Prof. Oellerich use Droplet Digital™ PCR to quantify early rejection biomarker.
Thursday, August 29, 2013
Accurate Quantification of NGS Libraries
A study has found that Droplet Digital PCR (ddPCR™) can be used as an accurate and precise method for quality control of NGS libraries.
Tuesday, August 20, 2013
New Biomarker Could Reveal Alzheimer's Disease Years Before Onset
A new study has reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD).
Wednesday, August 14, 2013
Producing Reliable Quantitative Western Blot Data
The reporting of fold changes in protein expression from western blots is often viewed with skepticism due to questions about the validity of the technique as a quantitative method.
Monday, June 17, 2013
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!